Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

N-terminal deletion does not affect α-synuclein membrane binding, self-association and toxicity in human neuroblastoma cells, unlike yeast.

Vamvaca K, Lansbury PT Jr, Stefanis L.

J Neurochem. 2011 Oct;119(2):389-97. doi: 10.1111/j.1471-4159.2011.07431.x. Epub 2011 Sep 20.

2.
3.

The first N-terminal amino acids of alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane binding in yeast.

Vamvaca K, Volles MJ, Lansbury PT Jr.

J Mol Biol. 2009 Jun 5;389(2):413-24. doi: 10.1016/j.jmb.2009.03.021. Epub 2009 Mar 13.

4.

Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Liu Z, Meray RK, Grammatopoulos TN, Fredenburg RA, Cookson MR, Liu Y, Logan T, Lansbury PT Jr.

Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4635-40. doi: 10.1073/pnas.0806474106. Epub 2009 Mar 4.

5.

Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, Fredenburg RA, Lansbury PT Jr, Fernandez CO, Eliezer D, Zweckstetter M, Lashuel HA.

J Biol Chem. 2008 Jun 13;283(24):16895-905. doi: 10.1074/jbc.M800747200. Epub 2008 Mar 14.

6.

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy.

Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, Dauer W, Przedborski S, Ischiropoulos H, Lansbury PT, Sulzer D, Cuervo AM.

J Clin Invest. 2008 Feb;118(2):777-88. doi: 10.1172/JCI32806.

7.

The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states.

Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, Eliezer D, Lansbury PT Jr.

Biochemistry. 2007 Jun 19;46(24):7107-18. Epub 2007 May 26.

PMID:
17530780
8.

Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1.

Meray RK, Lansbury PT Jr.

J Biol Chem. 2007 Apr 6;282(14):10567-75. Epub 2007 Jan 26.

9.
10.

Substrate recognition and catalysis by UCH-L1.

Luchansky SJ, Lansbury PT Jr, Stein RL.

Biochemistry. 2006 Dec 12;45(49):14717-25.

PMID:
17144664
11.

A century-old debate on protein aggregation and neurodegeneration enters the clinic.

Lansbury PT, Lashuel HA.

Nature. 2006 Oct 19;443(7113):774-9. Review.

PMID:
17051203
12.

Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?

Lashuel HA, Lansbury PT Jr.

Q Rev Biophys. 2006 May;39(2):167-201. Epub 2006 Sep 18. Review.

PMID:
16978447
13.

Improving synaptic function in a mouse model of AD.

Lansbury PT Jr.

Cell. 2006 Aug 25;126(4):655-7.

14.

Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.

Das C, Hoang QQ, Kreinbring CA, Luchansky SJ, Meray RK, Ray SS, Lansbury PT, Ringe D, Petsko GA.

Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4675-80. Epub 2006 Mar 13. Erratum in: Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6776.

15.

Your health in the 21st century. A fix for faulty proteins.

Lansbury PT, Fagan T.

Newsweek. 2005 Summer;145(26A):52. No abstract available.

PMID:
16375147
16.
17.

Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation.

Ray SS, Nowak RJ, Brown RH Jr, Lansbury PT Jr.

Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3639-44. Epub 2005 Feb 28.

18.

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D.

Science. 2004 Aug 27;305(5688):1292-5.

19.

Back to the future: the 'old-fashioned' way to new medications for neurodegeneration.

Lansbury PT Jr.

Nat Med. 2004 Jul;10 Suppl:S51-7. Review.

PMID:
15298008
20.

Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.

Rochet JC, Outeiro TF, Conway KA, Ding TT, Volles MJ, Lashuel HA, Bieganski RM, Lindquist SL, Lansbury PT.

J Mol Neurosci. 2004;23(1-2):23-34. Review.

PMID:
15126689
21.

An intersubunit disulfide bond prevents in vitro aggregation of a superoxide dismutase-1 mutant linked to familial amytrophic lateral sclerosis.

Ray SS, Nowak RJ, Strokovich K, Brown RH Jr, Walz T, Lansbury PT Jr.

Biochemistry. 2004 May 4;43(17):4899-905.

PMID:
15109247
22.

A possible therapeutic target for Lou Gehrig's disease.

Ray SS, Lansbury PT Jr.

Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5701-2. Epub 2004 Apr 12. No abstract available.

23.

Abeta protofibrils possess a stable core structure resistant to hydrogen exchange.

Kheterpal I, Lashuel HA, Hartley DM, Walz T, Lansbury PT Jr, Wetzel R.

Biochemistry. 2003 Dec 9;42(48):14092-8.

PMID:
14640676
24.

Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line.

Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT Jr.

Chem Biol. 2003 Sep;10(9):837-46.

PMID:
14522054
25.

Mixtures of wild-type and a pathogenic (E22G) form of Abeta40 in vitro accumulate protofibrils, including amyloid pores.

Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT Jr.

J Mol Biol. 2003 Sep 26;332(4):795-808.

PMID:
12972252
26.

Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.

Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL.

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9831-6. Epub 2003 Aug 4.

27.

Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.

Volles MJ, Lansbury PT Jr.

Biochemistry. 2003 Jul 8;42(26):7871-8. Review.

PMID:
12834338
28.

Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Caughey B, Lansbury PT.

Annu Rev Neurosci. 2003;26:267-98. Epub 2003 Apr 9. Review.

PMID:
12704221
29.
30.

The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation.

Kessler JC, Rochet JC, Lansbury PT Jr.

Biochemistry. 2003 Jan 28;42(3):672-8.

PMID:
12534279
31.
32.

Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr.

J Mol Biol. 2002 Oct 4;322(5):1089-102.

PMID:
12367530
33.
34.

Genetics of Parkinson's disease and biochemical studies of implicated gene products.

Lansbury PT Jr, Brice A.

Curr Opin Cell Biol. 2002 Oct;14(5):653-60. Review.

PMID:
12231362
35.
36.

Neurodegenerative disease: amyloid pores from pathogenic mutations.

Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr.

Nature. 2002 Jul 18;418(6895):291.

PMID:
12124613
37.

Genetics of Parkinson's disease and biochemical studies of implicated gene products.

Lansbury PT Jr, Brice A.

Curr Opin Genet Dev. 2002 Jun;12(3):299-306. Review.

PMID:
12076673
39.
40.

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr.

Science. 2001 Nov 9;294(5545):1346-9.

41.

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, Lansbury PT Jr.

Biochemistry. 2001 Jul 3;40(26):7812-9.

PMID:
11425308
42.

Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants.

Conway KA, Lee SJ, Rochet JC, Ding TT, Harper JD, Williamson RE, Lansbury PT Jr.

Ann N Y Acad Sci. 2000;920:42-5. Review. No abstract available.

PMID:
11193175
43.

Following nature's anti-amyloid strategy.

Lansbury PT Jr.

Nat Biotechnol. 2001 Feb;19(2):112-3. No abstract available.

PMID:
11175720
44.

An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

Fezoui Y, Hartley DM, Harper JD, Khurana R, Walsh DM, Condron MM, Selkoe DJ, Lansbury PT Jr, Fink AL, Teplow DB.

Amyloid. 2000 Sep;7(3):166-78.

45.

Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein.

Rochet JC, Conway KA, Lansbury PT Jr.

Biochemistry. 2000 Sep 5;39(35):10619-26.

PMID:
10978144
46.

Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update.

Caughey B, Raymond GJ, Priola SA, Kocisko DA, Race RE, Bessen RA, Lansbury PT Jr, Chesebro B.

Mol Biotechnol. 1999 Nov;13(1):45-55.

PMID:
10934521
47.

Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

Goldberg MS, Lansbury PT Jr.

Nat Cell Biol. 2000 Jul;2(7):E115-9.

PMID:
10878819
48.

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Conway KA, Harper JD, Lansbury PT Jr.

Biochemistry. 2000 Mar 14;39(10):2552-63.

PMID:
10704204
49.

Amyloid fibrillogenesis: themes and variations.

Rochet JC, Lansbury PT Jr.

Curr Opin Struct Biol. 2000 Feb;10(1):60-8. Review.

PMID:
10679462
50.

Neurodegeneration: new clues on inclusions.

Lansbury PT Jr, Kosik KS.

Chem Biol. 2000 Jan;7(1):R9-R12. Review.

Supplemental Content

Loading ...
Support Center